Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomalidomide - Celgene Corporation

Drug Profile

Pomalidomide - Celgene Corporation

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Brain cancer; Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Phase I Waldenstrom's macroglobulinaemia
  • No development reported Myelofibrosis; Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer

Most Recent Events

  • 29 Oct 2018 Celgene initiates an expanded-access programme for Multiple Myeloma in USA (NCT03723096)
  • 18 Oct 2018 AbbVie and Celgene initiate a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Spain (PO) (NCT03567616)
  • 01 Oct 2018 University of California, Celgene, Takeda and Janssen initiates enrolment in a phase II trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT03590652)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top